
Harvard Bioscience HBIO
$ 6.18
2.32%
Quarterly report 2026-Q1
added 05-12-2026
Harvard Bioscience Operating Cash Flow 2011-2026 | HBIO
Annual Operating Cash Flow Harvard Bioscience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.73 M | 1.44 M | 14 M | 1.15 M | 1.26 M | 9.33 M | 8.04 M | 2.88 M | 1.06 M | 5.38 M | 705 K | 4.35 M | 4.06 M | 8.06 M | 6.65 M | 12.3 M | 16.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 M | 705 K | 6.11 M |
Quarterly Operating Cash Flow Harvard Bioscience
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -662 K | - | - | 2.99 M | - | - | - | 1.4 M | - | - | - | 1.81 M | - | - | - | -1.99 M | - | - | - | 1.04 M | - | 6.84 M | 5.24 M | 2.87 M | - | 5.82 M | 2.67 M | 2.01 M | - | 291 K | 1.72 M | 448 K | - | 2 M | -135 K | -610 K | - | 3.66 M | 216 K | -726 K | - | -1.06 M | -981 K | -497 K | - | 3.09 M | 2.49 M | 2.49 M | - | 2.81 M | - | 576 K | - | 6.66 M | 4.15 M | 1.6 M | - | 4 M | - | 1.14 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.84 M | -1.99 M | 1.86 M |
Operating Cash Flow of other stocks in the Medical instruments industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
20 K | - | - | $ 810 M | ||
|
The Cooper Companies
COO
|
796 M | $ 68.16 | -0.67 % | $ 13.6 B | ||
|
Glaukos Corporation
GKOS
|
-14.8 M | $ 122.57 | -2.98 % | $ 7.01 B | ||
|
Alcon
ALC
|
1.34 B | $ 66.92 | -1.44 % | $ 40.4 B | ||
|
Intuitive Surgical
ISRG
|
3.03 B | $ 418.06 | -2.01 % | $ 149 B | ||
|
ICU Medical
ICUI
|
180 M | $ 142.66 | 0.46 % | $ 3.52 B | ||
|
iRhythm Technologies
IRTC
|
80.9 M | $ 114.32 | 0.43 % | $ 3.66 B | ||
|
Repro Med Systems
KRMD
|
462 K | $ 3.99 | -0.38 % | $ 184 M | ||
|
LeMaitre Vascular
LMAT
|
81.3 M | $ 95.36 | -1.28 % | $ 2.16 B | ||
|
Masimo Corporation
MASI
|
196 M | $ 179.95 | - | $ 9.59 B | ||
|
Microbot Medical
MBOT
|
-13 M | $ 1.8 | -1.37 % | $ 82.4 M | ||
|
Ekso Bionics Holdings
EKSO
|
-11.8 M | - | - | $ 28.6 M | ||
|
Milestone Scientific
MLSS
|
-2.92 M | $ 0.4 | 2.67 % | $ 32.8 M | ||
|
Merit Medical Systems
MMSI
|
297 M | $ 67.27 | -0.36 % | $ 3.98 B | ||
|
electroCore
ECOR
|
-8.19 M | $ 9.64 | 1.25 % | $ 81.8 K | ||
|
Envista Holdings Corporation
NVST
|
276 M | $ 24.65 | 0.24 % | $ 4.14 B | ||
|
Haemonetics Corporation
HAE
|
293 M | $ 79.6 | 1.13 % | $ 3.76 B | ||
|
Isoray
ISR
|
-82.5 M | - | 0.03 % | $ 108 M | ||
|
STERIS plc
STE
|
1.34 B | $ 210.28 | -1.16 % | $ 20.6 B | ||
|
STAAR Surgical Company
STAA
|
-34.2 M | $ 29.84 | -0.1 % | $ 1.48 B | ||
|
InfuSystem Holdings
INFU
|
24.4 M | $ 8.93 | -0.89 % | $ 184 M | ||
|
West Pharmaceutical Services
WST
|
755 M | $ 330.59 | -1.22 % | $ 23.9 B | ||
|
Utah Medical Products
UTMD
|
14.7 M | $ 68.56 | 0.72 % | $ 222 M | ||
|
Pulse Biosciences
PLSE
|
-54.1 M | $ 24.9 | -3.38 % | $ 1.68 B | ||
|
DENTSPLY SIRONA
XRAY
|
235 M | $ 10.39 | -0.81 % | $ 2.07 B | ||
|
Retractable Technologies
RVP
|
-7.06 M | $ 0.68 | -1.18 % | $ 20.4 M | ||
|
Pro-Dex
PDEX
|
-1.68 M | $ 63.12 | -2.89 % | $ 208 M | ||
|
Predictive Oncology
POAI
|
-13.2 M | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
20.1 M | $ 27.32 | -0.83 % | $ 1.3 B | ||
|
Stereotaxis
STXS
|
-13.7 M | $ 1.85 | -0.27 % | $ 168 M | ||
|
Baxter International
BAX
|
845 M | $ 20.55 | 2.6 % | $ 10.5 B | ||
|
ResMed
RMD
|
351 M | $ 196.09 | -0.43 % | $ 28.6 B | ||
|
AtriCure
ATRC
|
57.3 M | $ 27.3 | - | $ 1.3 B | ||
|
NeuroMetrix
NURO
|
-7.13 M | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
-10.1 M | $ 12.37 | 0.2 % | $ 505 M | ||
|
Becton, Dickinson and Company
BDX
|
3.33 B | $ 150.38 | -1.09 % | $ 43.3 B | ||
|
Nephros
NEPH
|
1.64 M | $ 3.24 | -0.46 % | $ 34.4 M | ||
|
OraSure Technologies
OSUR
|
-49 M | $ 4.17 | -1.77 % | $ 306 M | ||
|
Repligen Corporation
RGEN
|
117 M | $ 131.82 | 1.3 % | $ 7.41 M |